CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
ANBL09P1 COG A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma: A Limited Institution Pilot Study Pediatric CIRB
ANBL1021 COG Feasibility/Phase II Study of hu14.18-IL2 immunocytokine + GM-CSF and Isotretinoin in Patients with Relapsed or Refractory Neuroblastoma: A Groupwide Phase II Study Pediatric CIRB
ANBL1221 COG A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864; IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038; IND# 4308) in Children with Refractory; Relapsed or Progressive Neuroblastoma Pediatric CIRB
ANBL1232 COG Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study Pediatric CIRB
ANBL12P1 COG Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma Pediatric CIRB
ANBL1531 COG A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) Pediatric CIRB
ANBL17P1 COG A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma Pediatric CIRB
ANBL1821 COG A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive Neuroblastoma Pediatric CIRB
ANBL19P1 COG A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma Pediatric CIRB
ANBL2131 COG A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma Cancer Prevention and Control CIRB